Anne Goldberg, Professor of Medicine, Washington University School of Medicine, USA, discusses likely reasons for the disappointing PROMINENT trial results and is eager to find out if targeting apoCIII with either antisense oligonucleotide or mRNA silencing approaches may represent a way forward in treating patients with severe chylomicronaemia.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
